Chapter/Section Purchase

1 Study Coverage
1.1 Pulmonary Hypertension Drug Product Introduction
1.2 Market by Type
1.2.1 Global Pulmonary Hypertension Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 IK-3001
1.2.3 Sildenafil Citrate IMD
1.2.4 IK-7002
1.2.5 Riociguat
1.2.6 SAR-407899
1.2.7 Others
1.3 Market by Application
1.3.1 Global Pulmonary Hypertension Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Pulmonary Hypertension Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Pulmonary Hypertension Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Pulmonary Hypertension Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Pulmonary Hypertension Drug Sales by Region
2.4.1 Global Pulmonary Hypertension Drug Sales by Region (2017-2022)
2.4.2 Global Sales Pulmonary Hypertension Drug by Region (2023-2028)
2.5 Global Pulmonary Hypertension Drug Revenue by Region
2.5.1 Global Pulmonary Hypertension Drug Revenue by Region (2017-2022)
2.5.2 Global Pulmonary Hypertension Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Pulmonary Hypertension Drug Sales by Manufacturers
3.1.1 Global Top Pulmonary Hypertension Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Pulmonary Hypertension Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Pulmonary Hypertension Drug in 2021
3.2 Global Pulmonary Hypertension Drug Revenue by Manufacturers
3.2.1 Global Pulmonary Hypertension Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Pulmonary Hypertension Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Pulmonary Hypertension Drug Revenue in 2021
3.3 Global Pulmonary Hypertension Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Pulmonary Hypertension Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Pulmonary Hypertension Drug Sales by Type
4.1.1 Global Pulmonary Hypertension Drug Historical Sales by Type (2017-2022)
4.1.2 Global Pulmonary Hypertension Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Pulmonary Hypertension Drug Sales Market Share by Type (2017-2028)
4.2 Global Pulmonary Hypertension Drug Revenue by Type
4.2.1 Global Pulmonary Hypertension Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Pulmonary Hypertension Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Pulmonary Hypertension Drug Revenue Market Share by Type (2017-2028)
4.3 Global Pulmonary Hypertension Drug Price by Type
4.3.1 Global Pulmonary Hypertension Drug Price by Type (2017-2022)
4.3.2 Global Pulmonary Hypertension Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Pulmonary Hypertension Drug Sales by Application
5.1.1 Global Pulmonary Hypertension Drug Historical Sales by Application (2017-2022)
5.1.2 Global Pulmonary Hypertension Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Pulmonary Hypertension Drug Sales Market Share by Application (2017-2028)
5.2 Global Pulmonary Hypertension Drug Revenue by Application
5.2.1 Global Pulmonary Hypertension Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Pulmonary Hypertension Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Pulmonary Hypertension Drug Revenue Market Share by Application (2017-2028)
5.3 Global Pulmonary Hypertension Drug Price by Application
5.3.1 Global Pulmonary Hypertension Drug Price by Application (2017-2022)
5.3.2 Global Pulmonary Hypertension Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Pulmonary Hypertension Drug Market Size by Type
6.1.1 North America Pulmonary Hypertension Drug Sales by Type (2017-2028)
6.1.2 North America Pulmonary Hypertension Drug Revenue by Type (2017-2028)
6.2 North America Pulmonary Hypertension Drug Market Size by Application
6.2.1 North America Pulmonary Hypertension Drug Sales by Application (2017-2028)
6.2.2 North America Pulmonary Hypertension Drug Revenue by Application (2017-2028)
6.3 North America Pulmonary Hypertension Drug Market Size by Country
6.3.1 North America Pulmonary Hypertension Drug Sales by Country (2017-2028)
6.3.2 North America Pulmonary Hypertension Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Pulmonary Hypertension Drug Market Size by Type
7.1.1 Europe Pulmonary Hypertension Drug Sales by Type (2017-2028)
7.1.2 Europe Pulmonary Hypertension Drug Revenue by Type (2017-2028)
7.2 Europe Pulmonary Hypertension Drug Market Size by Application
7.2.1 Europe Pulmonary Hypertension Drug Sales by Application (2017-2028)
7.2.2 Europe Pulmonary Hypertension Drug Revenue by Application (2017-2028)
7.3 Europe Pulmonary Hypertension Drug Market Size by Country
7.3.1 Europe Pulmonary Hypertension Drug Sales by Country (2017-2028)
7.3.2 Europe Pulmonary Hypertension Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Pulmonary Hypertension Drug Market Size by Type
8.1.1 Asia Pacific Pulmonary Hypertension Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Pulmonary Hypertension Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Pulmonary Hypertension Drug Market Size by Application
8.2.1 Asia Pacific Pulmonary Hypertension Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Pulmonary Hypertension Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Pulmonary Hypertension Drug Market Size by Region
8.3.1 Asia Pacific Pulmonary Hypertension Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Pulmonary Hypertension Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Pulmonary Hypertension Drug Market Size by Type
9.1.1 Latin America Pulmonary Hypertension Drug Sales by Type (2017-2028)
9.1.2 Latin America Pulmonary Hypertension Drug Revenue by Type (2017-2028)
9.2 Latin America Pulmonary Hypertension Drug Market Size by Application
9.2.1 Latin America Pulmonary Hypertension Drug Sales by Application (2017-2028)
9.2.2 Latin America Pulmonary Hypertension Drug Revenue by Application (2017-2028)
9.3 Latin America Pulmonary Hypertension Drug Market Size by Country
9.3.1 Latin America Pulmonary Hypertension Drug Sales by Country (2017-2028)
9.3.2 Latin America Pulmonary Hypertension Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Pulmonary Hypertension Drug Market Size by Type
10.1.1 Middle East and Africa Pulmonary Hypertension Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Pulmonary Hypertension Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Pulmonary Hypertension Drug Market Size by Application
10.2.1 Middle East and Africa Pulmonary Hypertension Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Pulmonary Hypertension Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Pulmonary Hypertension Drug Market Size by Country
10.3.1 Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Overview
11.1.3 Sanofi Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Sanofi Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi Recent Developments
11.2 Vectura Group plc
11.2.1 Vectura Group plc Corporation Information
11.2.2 Vectura Group plc Overview
11.2.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Vectura Group plc Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Vectura Group plc Recent Developments
11.3 Bayer AG
11.3.1 Bayer AG Corporation Information
11.3.2 Bayer AG Overview
11.3.3 Bayer AG Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Bayer AG Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Bayer AG Recent Developments
11.4 Ikaria Inc.
11.4.1 Ikaria Inc. Corporation Information
11.4.2 Ikaria Inc. Overview
11.4.3 Ikaria Inc. Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Ikaria Inc. Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Ikaria Inc. Recent Developments
11.5 Proreo Pharma AG
11.5.1 Proreo Pharma AG Corporation Information
11.5.2 Proreo Pharma AG Overview
11.5.3 Proreo Pharma AG Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Proreo Pharma AG Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Proreo Pharma AG Recent Developments
11.6 Vicore Pharma AB
11.6.1 Vicore Pharma AB Corporation Information
11.6.2 Vicore Pharma AB Overview
11.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Vicore Pharma AB Recent Developments
11.7 Biolab Sanus Farmaceutica Ltda.
11.7.1 Biolab Sanus Farmaceutica Ltda. Corporation Information
11.7.2 Biolab Sanus Farmaceutica Ltda. Overview
11.7.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Biolab Sanus Farmaceutica Ltda. Recent Developments
11.8 Hanmi Pharmaceuticals, Co. Ltd.
11.8.1 Hanmi Pharmaceuticals, Co. Ltd. Corporation Information
11.8.2 Hanmi Pharmaceuticals, Co. Ltd. Overview
11.8.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Pulmonary Hypertension Drug Industry Chain Analysis
12.2 Pulmonary Hypertension Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pulmonary Hypertension Drug Production Mode & Process
12.4 Pulmonary Hypertension Drug Sales and Marketing
12.4.1 Pulmonary Hypertension Drug Sales Channels
12.4.2 Pulmonary Hypertension Drug Distributors
12.5 Pulmonary Hypertension Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Pulmonary Hypertension Drug Industry Trends
13.2 Pulmonary Hypertension Drug Market Drivers
13.3 Pulmonary Hypertension Drug Market Challenges
13.4 Pulmonary Hypertension Drug Market Restraints
14 Key Findings in The Global Pulmonary Hypertension Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer